Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock

7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their

BenzingaApr 23 02:00

Silence Therapeutics Is Maintained at Overweight by Morgan Stanley

Silence Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow JonesApr 23 01:39

Damo: Maintaining the Silence Therapeutics (SLN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $45.00 to $45.00.

Damo: Maintaining the Silence Therapeutics (SLN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $45.00 to $45.00.

Zhitong FinanceApr 23 01:30

Morgan Stanley Maintains Overweight on Silence Therapeutics, Maintains $45 Price Target

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and maintains $45 price target.

BenzingaApr 23 01:29

Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions

Key Insights Silence Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 54% of the business is held by the top

Simply Wall StApr 22 20:01

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down

European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains

MT NewswiresApr 19 23:10